TABLE 4.

The association of serum arginine (per SD) with site-specific cancer risk.

Arginine (μg/mL)	Cases/Control (Ratio 1:1)	Crude model		Adjusted model
		OR (95% CI)	p-value	OR (95% CI)	p-value
Lung cancer	361/361	1.22 (1.04, 1.43)	0.015	1.15 (0.96, 1.37)	0.131
Colorectal cancer	180/180	1.40 (1.10, 1.76)	0.006	1.35 (1.01, 1.82)	0.048
Gastric cancer	160/160	1.23 (0.95, 1.59)	0.118	1.34 (0.97, 1.86)	0.077
Liver cancer	107/107	0.87 (0.63, 1.19)	0.379	0.89 (0.58, 1.36)	0.589
Breast cancer	85/85	1.13 (0.82, 1.51)	0.487	1.05 (0.70, 1.59)	0.813
Head and neck cancer	82/82	1.67 (1.14, 2.44)	0.008	1.48 (0.93, 2.35)	0.096
Lymphoma and leukemia	57/57	1.19 (0.80, 1.78)	0.167	2.23 (0.72, 6.93)	0.167
Prostatic cancer	58/58	0.97 (0.68, 1.38)	0.878	0.90 (0.53, 1.53)	0.695
Pancreatic cancer	48/48	1.06 (0.68, 1.68)	0.788	0.57 (0.16.2.12)	0.405
Bladder cancer	41/41	1.07 (0.71, 1.59)	0.759	0.46 (0.14, 1.55)	0.210
Uterine and cervical cancer	47/47	0.90 (0.55, 1.47)	0.664	0.66 (0.31, 1.40)	0.282

Models were adjusted for ALT, ALB, BMI, smoking status, alcohol drinking, SBP, TC, TG, UA, HDL-C, glucose, creatinine, HCY, sleep quality, antihypertensive medication, and family history of cancer. Statistically significant values are shown in bold with all p values < 0.05.